What does CUSIP 68235C107 represent in this 13F holders report?

CUSIP 68235C107 is the security identifier for OCX - Oncocyte Corporation - Common Shares, No Par Value used to aggregate holder disclosures.

How many institutions held OCX - Oncocyte Corporation - Common Shares, No Par Value in Q2 2021?

88 institutional investors reported OCX - Oncocyte Corporation - Common Shares, No Par Value for Q2 2021. Use the holders table for investor-level position and value details.

Oncocyte Corporation - Common Shares, No Par Value (OCX)

CUSIP: 68235C107

Q2 2021 13F Holders as of 30 Jun 2021

Type / Class: Equity / Common Shares, No Par Value
Shares outstanding: 28,495,649
Total 13F shares: 56,557,145
Share change: +1,707,999
Total reported value: $324,629,337
Put/Call ratio: 48%
Price per share: $5.74
Number of holders: 88
Value change: +$10,097,713
Number of buys: 39
Number of sells: 42

Quarterly Holders Quick Answers

What is CUSIP 68235C107?
CUSIP 68235C107 identifies OCX - Oncocyte Corporation - Common Shares, No Par Value in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2021
Previous quarter: Q1 2021

Recent filing periods for CUSIP 68235C107:

Q2 2025 Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023

Top shareholders of OCX - Oncocyte Corporation - Common Shares, No Par Value (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
BROADWOOD CAPITAL INC	13F	Company	59%	16,776,484	$87,070,000	—	31 Mar 2021	13F
PURA VIDA INVESTMENTS, LLC	13F	Company	43%	12,223,953	$63,442,000	—	31 Mar 2021	13F
BlackRock Finance, Inc.	13F	Company	17%	4,968,214	$25,784,000	—	31 Mar 2021	13F
VANGUARD GROUP INC	13F	Company	13%	3,756,257	$19,495,000	—	31 Mar 2021	13F
ORBIMED ADVISORS LLC	13F	Company	7.4%	2,100,000	$10,899,000	—	31 Mar 2021	13F
Schonfeld Strategic Advisors LLC	13F	Company	5.7%	1,622,824	$8,423,000	—	31 Mar 2021	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	4%	1,141,078	$5,922,000	—	31 Mar 2021	13F
STATE STREET CORP	13F	Company	3.9%	1,109,356	$5,758,000	—	31 Mar 2021	13F
Nuveen Asset Management, LLC	13F	Company	3.4%	978,844	$5,081,000	—	31 Mar 2021	13F
GW&K Investment Management, LLC	13F	Company	2.7%	777,439	$4,035,000	—	31 Mar 2021	13F
AWM Investment Company, Inc.	13F	Company	2.6%	750,000	$3,892,000	—	31 Mar 2021	13F
NORTHERN TRUST CORP	13F	Company	2.6%	742,362	$3,853,000	—	31 Mar 2021	13F
Parian Global Management LP	13F	Company	2.4%	696,365	$3,614,000	—	31 Mar 2021	13F
Defender Capital, LLC.	13F	Company	2.1%	604,450	$3,122,000	—	31 Mar 2021	13F
MILLENNIUM MANAGEMENT LLC	13F	Company	2.1%	584,778	$3,035,000	—	31 Mar 2021	13F
TWO SIGMA ADVISERS, LP	13F	Company	1.9%	549,200	$2,850,000	—	31 Mar 2021	13F
Penbrook Management LLC	13F	Company	1.5%	423,775	$2,199,000	—	31 Mar 2021	13F
TWO SIGMA INVESTMENTS, LP	13F	Company	1.5%	421,542	$2,188,000	—	31 Mar 2021	13F
MARSHALL WACE, LLP	13F	Company	1.3%	358,670	$1,861,000	—	31 Mar 2021	13F
Soleus Capital Management, L.P.	13F	Company	1%	297,000	$1,541,000	—	31 Mar 2021	13F
Millrace Asset Group, Inc.	13F	Company	0.8%	228,040	$1,184,000	—	31 Mar 2021	13F
BRIDGEWAY CAPITAL MANAGEMENT, LLC	13F	Company	0.7%	200,300	$1,040,000	—	31 Mar 2021	13F
Maven Securities LTD	13F	Company	0.68%	193,348	$1,009,000	—	31 Mar 2021	13F
Bank of New York Mellon Corp	13F	Company	0.64%	183,484	$953,000	—	31 Mar 2021	13F
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	13F	Company	0.64%	182,544	$948,000	—	31 Mar 2021	13F
GOLDMAN SACHS GROUP INC	13F	Company	0.59%	168,779	$876,000	—	31 Mar 2021	13F
Private Wealth Partners, LLC	13F	Company	0.53%	150,000	$779,000	—	31 Mar 2021	13F
PRINCIPAL FINANCIAL GROUP INC	13F	Company	0.44%	126,387	$656,000	—	31 Mar 2021	13F
JPMORGAN CHASE & CO	13F	Company	0.44%	126,244	$655,000	—	31 Mar 2021	13F
NISA INVESTMENT ADVISORS, LLC	13F	Company	0.42%	120,000	$623,000	—	31 Mar 2021	13F
CITADEL ADVISORS LLC	13F	Company	0.41%	116,221	$603,000	—	31 Mar 2021	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.39%	110,300	$572,000	—	31 Mar 2021	13F
BARCLAYS PLC	13F	Company	0.38%	109,669	$569,000	—	31 Mar 2021	13F
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM	13F	Company	0.38%	107,507	$558,000	—	31 Mar 2021	13F
Fort Sheridan Advisors LLC	13F	Company	0.36%	103,000	$535,000	—	31 Mar 2021	13F
Squarepoint Ops LLC	13F	Company	0.29%	82,277	$427,000	—	31 Mar 2021	13F
MORGAN STANLEY	13F	Company	0.27%	76,335	$396,000	—	31 Mar 2021	13F
Polar Capital Holdings Plc	13F	Company	0.23%	66,529	$345,000	—	31 Mar 2021	13F
STATE OF WISCONSIN INVESTMENT BOARD	13F	Company	0.23%	66,100	$343,000	—	31 Mar 2021	13F
SUSQUEHANNA INTERNATIONAL GROUP, LLP	13F	Company	0.22%	61,781	$321,000	—	31 Mar 2021	13F
CALIBER WEALTH MANAGEMENT, LLC	13F	Company	0.21%	60,025	$312,000	—	31 Mar 2021	13F
DOHENY ASSET MANAGEMENT /CA	13F	Company	0.2%	57,900	$301,000	—	31 Mar 2021	13F
UBS Group AG	13F	Company	0.19%	54,350	$282,000	—	31 Mar 2021	13F
RHUMBLINE ADVISERS	13F	Company	0.18%	51,024	$265,000	—	31 Mar 2021	13F
BANK OF AMERICA CORP /DE/	13F	Company	0.18%	50,970	$265,000	—	31 Mar 2021	13F
AQR CAPITAL MANAGEMENT LLC	13F	Company	0.17%	49,368	$256,000	—	31 Mar 2021	13F
NEW YORK STATE COMMON RETIREMENT FUND	13F	Company	0.17%	48,100	$250,000	—	31 Mar 2021	13F
Cambridge Investment Research Advisors, Inc.	13F	Company	0.17%	47,600	$247,000	—	31 Mar 2021	13F
PRICE T ROWE ASSOCIATES INC /MD/	13F	Company	0.17%	47,273	$245,000	—	31 Mar 2021	13F
DEUTSCHE BANK AG\	13F	Company	0.17%	47,197	$245,000	—	31 Mar 2021	13F

Institutional Holders of Oncocyte Corporation - Common Shares, No Par Value (OCX) as of Q2 2021

As of 30 Jun 2021, Oncocyte Corporation - Common Shares, No Par Value (OCX) was held by 88 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 56,557,145 shares. The largest 10 holders included BROADWOOD CAPITAL INC, PURA VIDA INVESTMENTS, LLC, BlackRock Inc., VANGUARD GROUP INC, ORBIMED ADVISORS LLC, Nuveen Asset Management, LLC, Schonfeld Strategic Advisors LLC, Defender Capital, LLC., STATE STREET CORP, and GEODE CAPITAL MANAGEMENT, LLC. This page lists 88 institutional shareholders reporting positions in this security for the Q2 2021 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2021 vs Q1 2021 Across Filers

Q1 2021 holders

Q2 2021 holders

Holder diff

Investor	Q1 2021 Shares	Q2 2021 Shares	Share Diff	Share Chg %	Q1 2021 Value $	Q2 2021 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.